Hiroaki Tanaka

Title: Hiroaki Tanaka: Innovator in Cancer Therapy

Introduction

Hiroaki Tanaka is a prominent inventor based in Lausanne, Switzerland. He has made significant contributions to the field of cancer therapy through his innovative research and development of therapeutic methods.

Latest Patents

Hiroaki Tanaka holds a patent for "Methods of cancer therapy by inhibiting fusion polypeptides comprising fibroblast growth factor receptor 2 (FGFR2) and vinculin (VCL)." This patent describes fusion polypeptides that include an FGFR2 polypeptide and cDNAs that encode such fusion polypeptides. The methods outlined in the patent also include diagnosing the presence of these fusion polypeptides or a gene or RNA sequence coding for them in a sample from a subject. Furthermore, it details methods for treating tumors based on the results of such diagnoses. He has 1 patent to his name.

Career Highlights

Hiroaki Tanaka is currently employed at Debiopharm International S.A., a company known for its focus on innovative drug development. His work at Debiopharm has allowed him to explore and implement groundbreaking cancer therapies.

Collaborations

Throughout his career, Hiroaki has collaborated with notable colleagues, including Corinne Moulon and Anne Vaslin Chessex. These collaborations have further enhanced his research and development efforts in the field of cancer therapy.

Conclusion

Hiroaki Tanaka is a dedicated inventor whose work in cancer therapy is paving the way for new treatment methods. His innovative approaches and collaborations continue to contribute to advancements in medical science.